AbCellera Biologics Inc. Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount
AbCellera Biologics Inc. (ABCL) reported Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount of $200.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount · last filed 2026-02-24
- AbCellera Biologics Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2025 was $200.00K, a 98.80% decline from fiscal 2024.
- AbCellera Biologics Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2024 was $16.60M, a 822.22% increase from fiscal 2023.
- AbCellera Biologics Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2023 was $1.80M.
- AbCellera Biologics Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 12 month |
|---|---|
| 2025-12-31 | $200.00K 10-K · filed 2026-02-24 |
| 2024-12-31 | $16.60M 10-K · filed 2026-02-24 |
| 2023-12-31 | $1.80M 10-K · filed 2026-02-24 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
| 2021-12-31 | $1.70M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |